Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06333860
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-03-21
Brief Title:
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment Works Throughout the Whole Body
Sponsor:
AbbVie
Organization:
AbbVie